CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 03 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 May 2019.
- 03 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
- 11 May 2018 Status changed from not yet recruiting to recruiting.